Tag: Drug Law ⋅ Page 1

Professor Lietzan’s Research Analyzes Patent Terms for New Medicine

A recent article in Bloomberg Law, U.S. Patent System Crimps Drug Innovation for Toughest Diseases, looks at the research of Professor Erika Lietzan and Kristina M.L. Acri about how the development of new drugs is affected by the U.S. patent system. Their research will be published in a forthcoming article. Their empirical research looked at 642 approved drugs to determine…

Professor Lietzan to Attend Economics Institute for Law Professors

Professor Erika Lietzan was selected to attend the Thirty-Third Economics Institute for Law Professors, hosted by the Henry G. Manne Program in Law and Economic Studies at the Antonin Scalia Law School at George Mason University. Professor Lietzan researches, writes and teaches primarily in the areas of drug and device regulation, intellectual property and administrative law. This eight-day program is designed…

Citizen Petitions at the FDA: Professor Lietzan Interviewed by The Atlantic

Professor Erika Lietzan was recently interviewed by a reporter for The Atlantic in connection with the use of “citizen petitions” at the U.S. Food & Drug Administration (FDA). A recent article in the New England Journal of Medicine had pointed out that many petitions are filed by brand-name drug companies about products proposed by generic drug companies. Professor Lietzan commented…

Professor Lietzan Quoted on “Right to Try” Legislation

Professor Erika Lietzan was recently quoted in numerous papers around the country in connection with possible federal “right to try” legislation. Broadly speaking, the purpose of state “right to try” laws is to make it possible for terminally ill patients to receive unapproved drugs for treatment, if those drugs are currently in clinical trials and certain other conditions are met.…